VivoSeq
Other

SCLC

1

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

SCLC is an early-stage landscape with 1 program across 2 companies. The most active players are Shanghai Henlius Biotech, Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

1 program

Phase 1N

Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

HLX3901

Shanghai Henlius Biotech

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

7

clinical trials

Recruiting4 · 57%
Completed2 · 29%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Recruiting·NNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.·Phase 1/2·NCT07136285·27 enrolled
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
Recruiting·ZZhejiang Cancer Hospital·N/A·NCT05651802·220 enrolled
Serplulimab Combined With CCRT for LS-SCLC.
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06295926·96 enrolled
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 (DLL3 × DLL3 × CD3 × CD28 Tetra-specific Antibody) in Patients With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma
Recruiting·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 1·NCT07416695·138 enrolled
Pazopanib Maintenance for SCLC
Completed·SSamsung Medical Center·Phase 2·NCT01797874·97 enrolled
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00617409·69 enrolled
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Unknown status·CCentral European Society for Anticancer Drug Research·Phase 1·NCT03227016·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)